SVB Leerink

Close on the heels of announcing additional BARDA funding for its coronavirus vaccine candidate mRNA-1273, Moderna Inc (NASDAQ: MRNA) said Monday that it has commenced a late-stage study of the investigational vaccine in collaboration with the NIH and the BARDA. Moderna Sticks With July...

Moderna Inc (NASDAQ: MRNA) shares came under significant selling pressure Thursday afternoon following an adverse patent ruling, and the stock is adding to the losses in Friday's session.  Moderna Loses Patent Challenge: In an ongoing legal dispute, the Patent Trial and Appeal Board...

Moderna Inc's (NASDAQ: MRNA) coronavirus vaccine in development — mRNA-1273 — continues to inspire confidence among sell-side analysts. The Moderna Analyst: SVB Leerink analyst Mani Foroohar initiated coverage of Moderna with a Market Perform rating and $65 price target. The...

Moderna Inc (NASDAQ: MRNA) shares were bulldozing their way toward record highs Wednesday in reaction to the publication in the New England Journal of Medicine of detailed interim Phase 1 data for mRNA-1273, its SARS-CoV2 vaccine candidate. The Moderna Analysts: BofA Securities analyst...

Amarin Corporation plc (NASDAQ: AMRN) announced late Tuesday a settlement agreement with Apotex for resolving a patent lawsuit regarding a generic version of Amarin's drug Vascepa.  The Amarin Analysts: Cantor Fitzgerald analyst Louise Chen reaffirmed an Overweight rating and $35 price...

The weekend was abuzz with rumors of U.K. pharma giant AstraZeneca plc's (NYSE: AZN) reported interest in U.S.-based large-cap biopharma Gilead Sciences, Inc. (NASDAQ: GILD). The report polarized investors and the sell-side alike as they debated the pros and cons of a potential combination. A...

Amarin Corporation plc (NASDAQ: AMRN) shares, which were higher in after-hours trading Thursday following the company's announcement regarding a third-party pilot trial of its Vascepa in COVID-19, were giving back the gains Friday.  First Vascepa Generic Greenlighted The negative sentiment...

MacroGenics Inc (NASDAQ: MGNX) reported Tuesday after the close with forecast-beating first-quarter results and said it has adequate cash to operate into 2022. The company also issued an update on its clinical pipeline. The MacroGenics Analyst SVB Leerink analyst Jonathan Chang reiterated an...

Keros Therapeutics Inc (NASDAQ: KROS), a clinical-stage biopharma focused on the development of treatments for rare hematologic and musculoskeletal disorders, went public in April.  With the IPO quiet period expiring, analysts are starting coverage of the stock — and adopting a bullish...

Merck & Co., Inc. (NYSE: MRK) shares came under pressure in Tuesday's session after the pharma company lowered its full-year guidance. The Merck Analysts Cantor Fitzgerald analyst Louise Chen reiterated an Overweight rating and $107 price target. SVB Leerink analyst Daina Graybosch...

Nektar Therapeutics (NASDAQ: NKTR) crashed more than 30% Friday after the company reported a huge second-quarter sales miss. Nektar also said manufacturing problems may have impacted the results of several studies of its NKTR-214 cancer treatment drug, which it has been testing in combination with...